10-K: STERIS Fiscal 2026 Annual Results

STERIS reports strong fiscal 2026 growth with revenues rising 8.7% to $5.94 billion, driven by volume and pricing gains.

Summary

• Total revenues increased 8.7% to $5.936 billion for fiscal 2026 compared to $5.460 billion in fiscal 2025.
• Income from operations rose 27.1% to $1.102 billion, up from $866.6 million in the prior year.
• Gross profit margin improved to 44.2% from 44.0% in fiscal 2025.
• Free cash flow reached $982.9 million, an increase from $787.2 million in fiscal 2025.
• The company completed two tuck-in acquisitions in the Healthcare segment for $23.4 million.
• The Board authorized a new $1 billion share repurchase program, terminating the previous $500 million program.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, characterized by solid organic growth, improved operating leverage, and a healthy balance sheet, despite ongoing regulatory and litigation headwinds.

Positives

• Revenue growth of 8.7% reflects strong organic demand and pricing power across all three business segments.
• Operating income growth of 27.1% significantly outpaced revenue growth, demonstrating operational leverage.
• Free cash flow generation remains robust at $982.9 million, supporting dividends and share repurchases.
• Debt-to-total capital ratio improved to 21.3% from 23.6% in the prior year, strengthening the balance sheet.
• Successful completion of the Dental segment divestiture in fiscal 2025 allowed for significant debt reduction.

Negatives

• Operating margins were pressured by increased tariff costs and inflation, which partially offset productivity gains.
• Effective tax rate increased to 25.0% from 23.2% due to geographic income mix and withholding taxes.
• Capital equipment revenue growth in the AST segment declined during the fiscal year.

Risks

• Ongoing litigation and regulatory scrutiny regarding ethylene oxide (EO) emissions pose material financial and operational risks.
• Geopolitical instability and potential changes to international trade policies, including USMCA review, could disrupt supply chains.
• Reliance on single-sourced materials like cobalt-60 and EO creates vulnerability to supply shortages.
• Cybersecurity threats and the complexity of global data privacy regulations (GDPR) could lead to significant financial penalties.
• Potential for goodwill and intangible asset impairment charges given the $6 billion combined carrying value.

Future Outlook

Management expects to continue managing costs, growing through internal product and service development, investing in capacity and efficiency, and augmenting growth with strategic acquisitions.

Management Comments

• Management emphasizes a commitment to creating a healthier and safer world through infection prevention innovation.
• The company remains focused on Lean principles to drive productivity and operational efficiency across all segments.

Industry Context

StockSavvy.ai notes that STERIS continues to benefit from the aging global population and increased demand for medical procedures, positioning it well against competitors like Getinge, Stryker, and 3M in the infection prevention space.

Comparison to Industry Standards

• Operating margins remain competitive within the medical technology sector, supported by a high mix of recurring service and consumable revenues.
• The company's focus on contract sterilization (AST) provides a defensive moat compared to pure-play capital equipment manufacturers.
• The 21.3% debt-to-total capital ratio reflects a conservative balance sheet management style typical of large-cap medical device firms.

Management Changes

Corporate Governance

Legal Proceedings

• The company is resolving substantially all pending personal injury claims related to ethylene oxide (EO) emissions in Cook County, Illinois, through a $48.2 million settlement process.
• The company is contesting two notices of deficiency from the IRS regarding fiscal 2018 tax matters involving approximately $50 million in potential liability.

Related Party Transactions

• None disclosed beyond standard executive compensation and board-related matters.

Stakeholder Impact

• Shareholders benefit from increased share repurchase authorization and consistent dividend growth.
• Customers benefit from continued investment in infection prevention and sterilization capacity.
• Employees are impacted by ongoing restructuring and continuous improvement initiatives.

Next Steps

• Continue execution of the Restructuring Plan, which is substantially complete.
• Commence a multi-year project to invest in upgraded technology for service and sales workflows.
• Ongoing claims administration process for the Illinois EO litigation settlement.

Key Dates

Recommendation

The company demonstrates strong financial health, consistent revenue growth, and effective capital allocation, making it an attractive long-term hold for institutional investors despite the manageable risks associated with EO litigation.

Keywords

STERIS, Infection Prevention, Sterilization, Healthcare, Medical Devices, Applied Sterilization Technologies, Life Sciences, 10-K